- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04925778
Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate (PERSIST)
An Open-label, Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® (Monomethyl Fumarate) From Dimethyl Fumarate (PERSIST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multicenter, observational study evaluating GI symptoms in relapsing-remitting multiple sclerosis (RRMS) patients who switch from dimethyl fumarate (DMF) to Bafiertam® (monomethyl fumarate).
Adult patients with a diagnosis of RRMS receiving continuous treatment with DMF monotherapy and who are experiencing GI symptoms will be eligible to enroll in the study.
Patients will be identified and screened by chart review and invited to report GI Symptoms for one baseline week using a study app downloaded on their own smartphone/tablet. During this week, patients will continue their currently prescribed and remaining DMF treatment and will record their GI symptoms daily using the app.
At the end of the Baseline Period, patients will be asked to cease administration of the DMF, and to commence self-treatment with Bafiertam® 95 mg capsules twice a day (total daily dose of 380 mg) approximately 12 hours apart the following day for 28 days. They will be required to continue to record their GI symptoms each day.
On Day 28; End-of Study [EOS]) the patient's diary will be reviewed, adverse events (AE) recorded, and drug accountability performed.
Following EOS patients will be asked if they wish to continue Bafiertam® treatment. Those patients who elect to continue will be contacted one month and two months after EOS to ascertain if they remain on Bafiertam®.
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Key Inclusion Criteria:
- Male or non-pregnant female aged 18years and older.
- Diagnosis of RRMS (per McDonald 2010 Criteria) at screening [Polman 2011].
- Currently being treated with dimethyl fumarate (DMF; Tecfidera® or generic equivalent). At least 1 week and 1 day of continuous treatment with DMF monotherapy prior to initiation of Bafiertam®. Note: continuous treatment with DMF is defined as treatment uninterrupted by other disease-modifying treatment.
- GI symptoms (defined as any combination of abdominal pain, nausea, vomiting, diarrhea, constipation, bloating, or flatulence) while receiving treatment with DMF.
- Must be naïve to Bafiertam®.
- Additional inclusion criteria apply
Key Exclusion Criteria:
- Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold) [Lublin 2014].
- Females breastfeeding, pregnant, or planning to become pregnant; or women who have a positive pregnancy test result during screening.
- History of severe hypersensitivity (e.g., anaphylaxis or anaphylactoid reactions) to the active ingredient (monomethyl fumarate), dimethyl fumarate, diroximel fumarate (Vumerity®), or any of the excipients.
- Lymphocyte counts less than 1000/microliter. Any other clinically significant abnormalities in CBC, blood and urine chemistries, or liver function tests in the past 30 days.
- History of severe opportunistic infections (including progressive multifocal leukoencephalopathy (PML) and herpes zoster) or any clinically significant, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (other than MS), dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator.
- Any prior suspicion of PML.
9. Additional exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the frequency and severity of GI symptoms before and after switching to Bafiertam®.
Time Frame: 28 days
|
The GI tolerability of Bafiertam® following a switch from dimethyl fumarate will be assessed by determining the frequency and severity of GI events using a modified gastrointestinal symptom scale.
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Thomas W Lategan, D.Phil., Banner Life Sciences LLC
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BLS-11-403
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing Remitting Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on monomethyl fumarate
-
Banner Life Sciences LLCEnrolling by invitationRelapsing Remitting Multiple SclerosisUnited States, Puerto Rico
-
Banner Life Sciences LLCCompletedRelapsing Remitting Multiple SclerosisUnited States
-
Banner Life Sciences LLCCompletedMultiple SclerosisUnited States
-
Banner Life Sciences LLCCompletedRelapsing Remitting Multiple Sclerosis
-
Swiss Federal Institute of TechnologyUniversity of Zurich; University Children's Hospital, Zurich; Jomo Kenyatta University...CompletedAnemia, Iron-deficiencyKenya
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Swiss Federal Institute of TechnologyCompletedIron-deficiencySwitzerland
-
University Health Network, TorontoActive, not recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Relapsed Cancer | Refractory CancerCanada
-
Medical University of ViennaTerminatedOcular Physiology | Regional Blood FlowAustria
-
BiogenCompletedHealthy VolunteersNew Zealand, Hong Kong